In the current study, we showed that PI3K inhibitor BKM120 as single-agent or in combination with Olaparib nearly completely abolished p-S6RP signals in the in vitro cell models of ovarian cancer (SKOV3, IGROV1, HEYA8) that respond well to drug treatment. This evidence concerns the gene PIK3CA and ovarian cancer.